Evidence map›Paper›PMID 35527903›Full record

ArticleRSC advances2019

Narjatamanins A and B, a pair of novel epimers possessing a 2,3-

Ye Zhao, Bing Li, Yi-Fan Yu, Pei-Qian Wu, Chun-Xue Yu, Pan-Jie Su, De-Juan Zhi, Feng-Ming Qi, Dong-Qing Fei, Zhan-Xin Zhang

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in RSC advances, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
1.8field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 8 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 1 institution in 1 country.

Ye ZhaoSchool of Pharmacy, Lanzhou University Lanzhou 730000 People's Republic of China feidq@lzu.edu.cn zhangzhx@lzu.edu.cn.
Bing LiSchool of Pharmacy, Lanzhou University Lanzhou 730000 People's Republic of China feidq@lzu.edu.cn zhangzhx@lzu.edu.cn.
Yi-Fan YuSchool of Pharmacy, Lanzhou University Lanzhou 730000 People's Republic of China feidq@lzu.edu.cn zhangzhx@lzu.edu.cn.
Pei-Qian WuSchool of Pharmacy, Lanzhou University Lanzhou 730000 People's Republic of China feidq@lzu.edu.cn zhangzhx@lzu.edu.cn.
Chun-Xue YuSchool of Pharmacy, Lanzhou University Lanzhou 730000 People's Republic of China feidq@lzu.edu.cn zhangzhx@lzu.edu.cn.
Pan-Jie SuSchool of Pharmacy, Lanzhou University Lanzhou 730000 People's Republic of China feidq@lzu.edu.cn zhangzhx@lzu.edu.cn.
De-Juan ZhiSchool of Pharmacy, Lanzhou University Lanzhou 730000 People's Republic of China feidq@lzu.edu.cn zhangzhx@lzu.edu.cn.
Feng-Ming QiState Key Laboratory of Applied Organic Chemistry, Lanzhou University Lanzhou 730000 People's Republic of China.
Dong-Qing FeiSchool of Pharmacy, Lanzhou University Lanzhou 730000 People's Republic of China feidq@lzu.edu.cn zhangzhx@lzu.edu.cn.ORCID https://orcid.org/0000-0002-5332-8347
Zhan-Xin ZhangSchool of Pharmacy, Lanzhou University Lanzhou 730000 People's Republic of China feidq@lzu.edu.cn zhangzhx@lzu.edu.cn.ORCID https://orcid.org/0000-0002-7892-9851
State Council of the People's Republic of China · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Narjatamanins A (1) and B (2), a pair of epimers possessing a novel 2,3-

Identifiers

PMID35527903
PMCPMC9069666
OpenAlexW2965751074

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.